Cargando…

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes in patients by t(11;14) status compared with high- and sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atrash, Shebli, Flahavan, Evelyn M., Xu, Tao, Ma, Esprit, Karve, Sudeep, Hong, Wan-Jen, Jirau-Lucca, Gilbert, Nixon, Michael, Ailawadhi, Sikander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943165/ https://www.ncbi.nlm.nih.gov/pubmed/35322025 http://dx.doi.org/10.1038/s41408-022-00638-0

Ejemplares similares

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: ATRASH, Shebli, et al.
Publicado: (2021)

Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification
por: Abdel-Qader, Hadeel Yaseen, et al.
Publicado: (2022)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Atrash, Shebli, et al.
Publicado: (2021)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
por: Jayakrishnan, Thejus, et al.
Publicado: (2021)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
por: Atrash, Shebli, et al.
Publicado: (2023)

Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population
por: Udupa, Chethana Babu K, et al.
Publicado: (2020)

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping
por: Díaz-González, Álvaro, et al.
Publicado: (2023)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Global disparities in patients with multiple myeloma: a rapid evidence assessment
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
por: Chng, Wee-Joo, et al.
Publicado: (2023)

Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification
por: Mahmood, Rafia, et al.
Publicado: (2018)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Interpretation of cytogenetic results in multiple myeloma for clinical practice
por: Rajan, A M, et al.
Publicado: (2015)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Lee, Philip, et al.
Publicado: (2022)

The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection
por: Peeters, Pascale, et al.
Publicado: (2019)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
por: Bonello, Francesca, et al.
Publicado: (2022)

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
por: Gonsalves, Wilson I., et al.
Publicado: (2018)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

Conventional and Molecular Cytogenetic Analyses in Turkish Patients with Multiple Myeloma
por: Durak, Beyhan Aras, et al.
Publicado: (2012)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma
por: Yang, Naery, et al.
Publicado: (2018)

Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)
por: Ehsan, Hamid, et al.
Publicado: (2023)

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
por: Ferreri, Christopher J., et al.
Publicado: (2023)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0eel01he5m6jd0vaiu1q6tegv2